Cyclic permutation

• NEW YORK, Jan. 22, 2024 /PRNewswire/ -- The lithium-sulfur battery market size is expected to grow by USD 1.76 billion from 2022 to 2027, according to Technavio.
• In addition, the growth momentum of the market will progress at a CAGR of 33.06% during the forecast period.
• The US, a major contributor to North America's Li-S battery market revenue, experiences high drone and EV adoption, necessitating batteries with extended runtime.
• The train battery market is estimated to grow at a CAGR of 5.45% between 2022 and 2027.

• Pathway to Cures (P2C) announced today its investment of $500,000 in Five Liters, a subsidiary of Spark Biomedical, to develop therapies for treating inheritable blood and bleeding disorders.
• Pathway to Cures, an affiliate of the National Bleeding Disorders Foundation, is a venture philanthropy fund focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.
• This significant milestone is made possible through Five Liters' collaboration with Northwell Health’s Feinstein Institutes for Medical Research in New York.
• Dr. Recht is Chief Medical and Scientific Officer at both Pathway to Cures and the National Bleeding Disorders Foundation (NBDF) and chairs the Pathway to Cures Scientific Advisory Group.

• Five Liters, a subsidiary of Spark Biomedical, is dedicated to exploring the hemostatic effects of vagus nerve stimulation (VNS), specifically transcutaneous auricular neurostimulation (tAN).
• Dr. Navid Khodaparast, Chief Science Officer of Spark and Five Liters stated “Von Willebrand Disease is an inherited bleeding disorder in which blood does not clot properly, leading to bleeding events and joint problems.
• At Five Liters, our primary clinical initiative is to demonstrate that tAN therapy can safely alleviate menorrhagia in females with VWD.
• Thanks to this partnership and the Nature article, Five Liters is thrilled to move forward with its mission.

• Yet many people have never heard of this condition, despite it affecting as many as one in five women.
• The severity of symptoms varies between patients – up to one-third of women with adenomyosis may have minimal or no symptoms at all.
• Women with adenomyosis who do become pregnant have an increased risk of miscarriage, pre-term delivery, pre-eclampsia and bleeding after delivery.

What causes adenomyosis?

• In people with adenomyosis, endometrium-like cells are found in the wrong place – the myometrium.
• Although a large number of women with adenomyosis have endometriosis as well, adenomyosis is a distinct disease from endometriosis.
• Read more:
  Adenomyosis causes pain, heavy periods and infertility but you've probably never heard of it

Diagnosis options are changing and improving

• Recent years have seen increased diagnoses with the development of imaging technologies such as MRI and detailed pelvic ultrasound.
• Although adenomyosis is now commonly identified without the need for a hysterectomy, doctors are still working towards developing a standardised method for non-surgical diagnosis.

Adenomyosis is a complex condition

• Adenomyosis can be further classified depending on the depth of endometrial-like tissue invasion into the myometrium.
• We don’t yet understand why some women develop adenomyosis, though evidence shows there is an increasing prevalence with age.
• It’s possible that a variety of mechanisms may contribute, and that there is not one common disease-causing factor behind adenomyosis.

How is adenomyosis treated?

• Treatments that work for some women don’t for others, adding weight to the argument that there’s more than one type of adenomyosis.
• Treatment strategies should be tailored to patients, depending on their fertility wishes and symptoms.
• If medical treatments are not providing adequate relief from symptoms, there are surgical options, namely removal of the focal lesions or a hysterectomy.

What lies ahead?

• There is also a lack of knowledge and awareness around adenomyosis among many healthcare professionals and the public.
• This needs to change so we can improve our understanding of the condition, diagnosis and treatment options.